Try our beta test site
844 studies found for:    Erlotinib
Show Display Options
Rank Status Study
1 Completed Erlotinib in Higher Risk Myelodysplastic Syndrome
Condition: Myelodysplastic Syndrome
Intervention: Drug: Erlotinib
2 Unknown  Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC
Condition: Non-small Cell Lung Cancer
Intervention: Drug: erlotinib
3 Completed Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC
Conditions: Squamous Cell Carcinoma;   Non-Small Cell Lung Cancer
Intervention: Drug: Erlotinib + Rosuvastatin
4 Completed Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
Conditions: Cancer;   Pancreas
Intervention: Drug: Erlotinib
5 Terminated
Has Results
Single-agent Erlotinib in Patients Previously Treated With Oral Etoposide in Protocol OSI-774-205
Condition: Ependymoma
Intervention: Drug: Erlotinib
6 Active, not recruiting Erlotinib Prior to Surgery in Patients With Head and Neck Cancer
Condition: Head And Neck Cancer
Intervention: Drug: Erlotinib
7 Completed
Has Results
A Trial of Erlotinib + Radiotherapy for Cutaneous Squamous Cell Carcinoma
Condition: Cancer
Intervention: Drug: Erlotinib
8 Recruiting Phase I Chemoprevention Trial With Green Tea Polyphenon E & Erlotinib in Patients With Premalignant Lesions of the Head & Neck
Conditions: Cancer of Head and Neck;   Neoplasms, Head and Neck
Interventions: Drug: Erlotinib;   Dietary Supplement: Green Tea Polyphenon E
9 Terminated
Has Results
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
Condition: Pancreatic Cancer
Intervention: Drug: erlotinib
10 Active, not recruiting Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BKM120 and Erlotinib
11 Recruiting A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline
Conditions: Non-small Cell Lung Cancer;   Advanced Solid Malignancies
Interventions: Drug: Theophylline;   Drug: Erlotinib
12 Active, not recruiting Neoadjuvant Erlotinib (Tarceva) in Transitional Cell Carcinoma
Condition: Transitional Cell Carcinoma
Intervention: Drug: Erlotinib Hydrochloride
13 Recruiting Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
Conditions: NSCLC;   EGFR Mutation
Intervention: Drug: Erlotinib
14 Active, not recruiting Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer
Condition: EGFR-Mutant Lung Cancer
Intervention: Drug: erlotinib
15 Completed A Study of ARQ 197 in Combination With Erlotinib
Condition: Non-small-cell Lung Cancer
Intervention: Drug: ARQ 197 and Erlotinib
16 Completed Surgery for Early Lung Cancer With Preoperative Erlotinib (Tarceva): A Clinical Phase II Trial (SELECT)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: Erlotinib
17 Completed Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer
Conditions: Non-Small Cell Lung Cancer;   Brain Metastases
Intervention: Drug: erlotinib
18 Terminated
Has Results
Second Line Erlotinib (Tarceva) Plus Digoxin in Non-Small Cell Lung Cancer
Condition: Carcinoma, Non-Small Cell Lung
Intervention: Drug: Erlotinib plus Digoxin
19 Suspended Study to Assess Safety and Tolerability of MLN8237, In Combination With Erlotinib to Treat Non-Small Cell Lung Cancer
Conditions: Non-small Cell Lung Cancer Metastatic;   Non-small Cell Lung Cancer Recurrent
Intervention: Drug: MLN8237 and Erlotinib
20 Completed Erlotinib and Sirolimus in Treating Patients With Recurrent Malignant Glioma
Condition: Brain and Central Nervous System Tumors
Intervention: Drug: Erlotinib + Sirolimus

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.